Monkeypox virus(MPXV),a member of the Orthopoxvirus genus,caused a large-scale global outbreak in 2022.Developing mouse models for MPXV infection is crucial for advancing research on vaccines and therapeutic intervent...Monkeypox virus(MPXV),a member of the Orthopoxvirus genus,caused a large-scale global outbreak in 2022.Developing mouse models for MPXV infection is crucial for advancing research on vaccines and therapeutic interventions.To address this,we conducted a comparative study on the susceptibility of six mouse strains—severe combined immune-deficiency(SCID),nude,genetically diabetic(db/db)and obese(ob/ob),C57BL/6J,and BALB/c—to MPXV infection.Mouse strains were infected with MPXV via intranasal inoculation,and body weight changes and mortality were monitored post-infection.Additionally,the tissue distribution of MPXV and the pathological changes in the lung tissues of the infected mice were evaluated.The results demonstrated that SCID and nude mice exhibited significant weight loss following MPXV infection,with 100%mortality observed in SCID mice,while no mortality occurred in nude mice.In contrast,the other mouse strains showed no significant weight loss or mortality.Notably,the viral load in the lung tissues of SCID and nude mice was the highest among the tested strains.Furthermore,we investigated the impact of different inoculation routes—intranasal(I.N.),intraperitoneal(I.P.),and intravenous(I.V.)—on the pathogenicity of MPXV in mice.The results revealed that the intravenous route induced more pronounced pathogenic effects compared to the intranasal and intraperitoneal routes.In summary,this study provides valuable insights into the development of MPXV-infected mouse models,offering a foundation for further research on MPXV pathogenesis and therapeutic drug development.展开更多
The mpox virus(MPXV)is undergoing mutations at an alarmingly rapid pace,necessitating heightened genomic surveil-lance to manage its global spread.However,current assessments lack a comprehensive evaluation of genomic...The mpox virus(MPXV)is undergoing mutations at an alarmingly rapid pace,necessitating heightened genomic surveil-lance to manage its global spread.However,current assessments lack a comprehensive evaluation of genomic varia-tions and the influence of environmental and social factors.To address this gap,we developed the mpox virus variations risk evaluation system(VarEPS-MPXV),which uses a multidimensional strategy to assess observed and virtual varia-tions-those that have yet to occur-thereby mitigating time-lag issues in risk prediction.The system integrates six environmental and four social factors to monitor their impact on genomic variation.By analyzing 17,523 publicly avail-able MPxV sequences,we identified 61,788 unique amino acid variants and highlighted five significant mutations.Notably,OPG118:K606E is predicted to play a critical role in MPXV survival and transmission.Our assessment revealed that most key mutations involved amino acid substitutions with low mutational bariers.Variations in the OPG190 gene may alter antibody affinity,while the mutation at site 127 in the OPG038 gene may influence immune protein binding sta-bility.The VarEPS-MPXV offers vital support for managing MPXV outbreaks and other viral diseases,contributing to global public health research and practice.Researchers can freely access the database at https://nmdc.cn/mpox/.展开更多
The largest monkeypox virus(MPXV)outbreak of the 21st century occurred in 2022,which caused epidemics in many countries.According to WHO,physical contact with infected persons,contaminated surfaces,or affected animals...The largest monkeypox virus(MPXV)outbreak of the 21st century occurred in 2022,which caused epidemics in many countries.According to WHO,physical contact with infected persons,contaminated surfaces,or affected animals might be a source of this virus transmission.A febrile sickness including few symptoms found in MPX disease.Skin rash,lesions,fever,headache,fatigue,and muscle aches symptoms were observed commonly for this disease.Animal and in vitro,studies have shown that the antiviral medications cidofovir and brincidofovir are effective against MPXV.The first-generation vaccinia virus vaccine was developed in 1960,and it helped to protect against MPXV with its side effects.A second-generation vaccination with limitations was launched in 2000.However,the CDC advised vaccinations for risk groups in endemic countries,including positive patients and hospital employees.The JYNNEOS vaccine,administered in 2 doses,also provides protection from MPX.This article presents concisely the most recent findings regarding epidemiology,genomic transmission,signs and symptoms,pathogenesis,diagnosis,and therapeutic interventions for MPXV,which may be helpful to researchers and practitioners.WHO declared that MPX was no longer a global health emergency due to its declining case rate,and a number of countries have reported new incidences.Further research-based investigations must be carried out based on the 2022 outbreak.展开更多
Human monkeypox(MPX)is a rare zoonotic infection characterized by smallpox-like signs and symptoms.It is caused by monkeypox virus(MPXV),a double stranded DNA virus belonging to the genus Orthopoxvirus.MPX was first i...Human monkeypox(MPX)is a rare zoonotic infection characterized by smallpox-like signs and symptoms.It is caused by monkeypox virus(MPXV),a double stranded DNA virus belonging to the genus Orthopoxvirus.MPX was first identified in 1970 and mostly prevailed in the rural rainforests of Central and West Africa in the past.Outside Africa,MPX was reported in the United Kingdom,the USA,Israel,and Singapore.In 2022,the resurgence of MPX in Europe and elsewhere posed a potential threat to humans.MPXV was transmitted by the animals-human or human-human pathway,and the symptoms of MPXV infection are similar to that of smallpox,but in a milder form and with lower mortality(1%–10%).Although the smallpox vaccination has been shown to provide 85%protection against MPXV infection,and two anti-smallpox virus drugs have been approved to treat MPXV,there are still no specific vaccines and drugs against MPXV infection.Therefore it is urgent to take active measures including the adoption of novel anti-MPXV strategies to control the spread of MPXV and prevent MPX epidemic.In this review,we summarize the biological features,epidemiology,pathogenicity,laboratory diagnosis,and prevention and treatment strategies on MPXV.This review provides the basic knowledge for prevention and control of future outbreaks of this emerging infection.展开更多
基金financially supported by the National Key Research and Development Program of China(No.2023YFD1800403 and 2023YFD1800404)。
文摘Monkeypox virus(MPXV),a member of the Orthopoxvirus genus,caused a large-scale global outbreak in 2022.Developing mouse models for MPXV infection is crucial for advancing research on vaccines and therapeutic interventions.To address this,we conducted a comparative study on the susceptibility of six mouse strains—severe combined immune-deficiency(SCID),nude,genetically diabetic(db/db)and obese(ob/ob),C57BL/6J,and BALB/c—to MPXV infection.Mouse strains were infected with MPXV via intranasal inoculation,and body weight changes and mortality were monitored post-infection.Additionally,the tissue distribution of MPXV and the pathological changes in the lung tissues of the infected mice were evaluated.The results demonstrated that SCID and nude mice exhibited significant weight loss following MPXV infection,with 100%mortality observed in SCID mice,while no mortality occurred in nude mice.In contrast,the other mouse strains showed no significant weight loss or mortality.Notably,the viral load in the lung tissues of SCID and nude mice was the highest among the tested strains.Furthermore,we investigated the impact of different inoculation routes—intranasal(I.N.),intraperitoneal(I.P.),and intravenous(I.V.)—on the pathogenicity of MPXV in mice.The results revealed that the intravenous route induced more pronounced pathogenic effects compared to the intranasal and intraperitoneal routes.In summary,this study provides valuable insights into the development of MPXV-infected mouse models,offering a foundation for further research on MPXV pathogenesis and therapeutic drug development.
基金work was supported by various funding sources,including the National Key Research Program of China(2022YFC2303400 to C.S.)the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB0830000 to L.W.)+1 种基金the Key Research Programof the Chi-nese Academy of Sciences(KFZD-SW-219 to L.W.)the Shenzhen Medical Research Fund(E24010010 to Z.L.and E24010011 to Z.L.).
文摘The mpox virus(MPXV)is undergoing mutations at an alarmingly rapid pace,necessitating heightened genomic surveil-lance to manage its global spread.However,current assessments lack a comprehensive evaluation of genomic varia-tions and the influence of environmental and social factors.To address this gap,we developed the mpox virus variations risk evaluation system(VarEPS-MPXV),which uses a multidimensional strategy to assess observed and virtual varia-tions-those that have yet to occur-thereby mitigating time-lag issues in risk prediction.The system integrates six environmental and four social factors to monitor their impact on genomic variation.By analyzing 17,523 publicly avail-able MPxV sequences,we identified 61,788 unique amino acid variants and highlighted five significant mutations.Notably,OPG118:K606E is predicted to play a critical role in MPXV survival and transmission.Our assessment revealed that most key mutations involved amino acid substitutions with low mutational bariers.Variations in the OPG190 gene may alter antibody affinity,while the mutation at site 127 in the OPG038 gene may influence immune protein binding sta-bility.The VarEPS-MPXV offers vital support for managing MPXV outbreaks and other viral diseases,contributing to global public health research and practice.Researchers can freely access the database at https://nmdc.cn/mpox/.
文摘The largest monkeypox virus(MPXV)outbreak of the 21st century occurred in 2022,which caused epidemics in many countries.According to WHO,physical contact with infected persons,contaminated surfaces,or affected animals might be a source of this virus transmission.A febrile sickness including few symptoms found in MPX disease.Skin rash,lesions,fever,headache,fatigue,and muscle aches symptoms were observed commonly for this disease.Animal and in vitro,studies have shown that the antiviral medications cidofovir and brincidofovir are effective against MPXV.The first-generation vaccinia virus vaccine was developed in 1960,and it helped to protect against MPXV with its side effects.A second-generation vaccination with limitations was launched in 2000.However,the CDC advised vaccinations for risk groups in endemic countries,including positive patients and hospital employees.The JYNNEOS vaccine,administered in 2 doses,also provides protection from MPX.This article presents concisely the most recent findings regarding epidemiology,genomic transmission,signs and symptoms,pathogenesis,diagnosis,and therapeutic interventions for MPXV,which may be helpful to researchers and practitioners.WHO declared that MPX was no longer a global health emergency due to its declining case rate,and a number of countries have reported new incidences.Further research-based investigations must be carried out based on the 2022 outbreak.
基金the Natural Science Foundation of Hebei Province,China(no.H2020206352)the National Natural Science Foundation of China(no.81902026)+1 种基金Science and Technology Project of Hebei Education Department(no.BJ2020018)Project for the Introduction overseas students of Hebei Provincial Department of Human Resources and Social Security(no.C20200344)。
文摘Human monkeypox(MPX)is a rare zoonotic infection characterized by smallpox-like signs and symptoms.It is caused by monkeypox virus(MPXV),a double stranded DNA virus belonging to the genus Orthopoxvirus.MPX was first identified in 1970 and mostly prevailed in the rural rainforests of Central and West Africa in the past.Outside Africa,MPX was reported in the United Kingdom,the USA,Israel,and Singapore.In 2022,the resurgence of MPX in Europe and elsewhere posed a potential threat to humans.MPXV was transmitted by the animals-human or human-human pathway,and the symptoms of MPXV infection are similar to that of smallpox,but in a milder form and with lower mortality(1%–10%).Although the smallpox vaccination has been shown to provide 85%protection against MPXV infection,and two anti-smallpox virus drugs have been approved to treat MPXV,there are still no specific vaccines and drugs against MPXV infection.Therefore it is urgent to take active measures including the adoption of novel anti-MPXV strategies to control the spread of MPXV and prevent MPX epidemic.In this review,we summarize the biological features,epidemiology,pathogenicity,laboratory diagnosis,and prevention and treatment strategies on MPXV.This review provides the basic knowledge for prevention and control of future outbreaks of this emerging infection.
